The Common Fund’s Knockout Mouse Phenotyping Program (KOMP2) provides broad, standardized phenotyping of a genome-wide collection of mouse knockouts generated by the International Knockout Mouse Consortium (IKMC), funded by the NIH, European Union, Wellcome Trust, Canada, and the Texas Enterprise Fund.
New! Funding Opportunity Announcement to phenotype embryonic lethal knockout mice from the International Mouse Phenotyping Consortium (IMPC)!
The IMPC, a worldwide consortium that includes KOMP2 as a member, is generating an estimated 20,000 knockout mouse strains, up to 30% of which are expected to be embryonic or perinatal lethal. This funding opportunity announcement invites applications to phenotype embryonic lethal mouse strains with a long term goal of revealing important insights into normal development in addition to a variety of diseases. This funding opportunity is supported by several NIH Institutes and Centers, and is related to, but separate from, the Common Fund’s KOMP2 program.
Read the Funding Opportunity here.
NEW! Updates from KOMP2
See what KOMP2 has been doing lately! Download slides about KOMP2 history, current status, and future directions here.
Diagram showing overview of the KOMP2 phenotyping process. Building on resources derived from IKMC, standardized phenotyping of mutant mouse strains will be performed and data stored in a centralized database.
KOMP2 is partnering with organizations from ten countries as part of the International Mouse Phenotyping Consortium (IMPC) in an internationally coordinated effort to undertake a broad-based, systematic genome-wide phenotyping of knockout mice.
Visit the IMPC website here
Read more about the IMPC Informatics Team here